199 related articles for article (PubMed ID: 28246464)
1. In vitro anti-cancer activity of doxorubicin against human RNA helicase, DDX3.
Botlagunta M; Kollapalli B; Kakarla L; Gajarla SP; Gade SP; Dadi CL; Penumadu A; Javeed S
Bioinformation; 2016; 12(7):347-353. PubMed ID: 28246464
[TBL] [Abstract][Full Text] [Related]
2. NZ51, a ring-expanded nucleoside analog, inhibits motility and viability of breast cancer cells by targeting the RNA helicase DDX3.
Xie M; Vesuna F; Botlagunta M; Bol GM; Irving A; Bergman Y; Hosmane RS; Kato Y; Winnard PT; Raman V
Oncotarget; 2015 Oct; 6(30):29901-13. PubMed ID: 26337079
[TBL] [Abstract][Full Text] [Related]
3. Ketorolac salt is a newly discovered DDX3 inhibitor to treat oral cancer.
Samal SK; Routray S; Veeramachaneni GK; Dash R; Botlagunta M
Sci Rep; 2015 Apr; 5():9982. PubMed ID: 25918862
[TBL] [Abstract][Full Text] [Related]
4. Molecular docking, synthesis, and biological evaluation of 7-azaindole-derivative (7AID) as novel anti-cancer agent and potent DDX3 inhibitor:-an in silico and in vitro approach.
Doneti R; Pasha A; Botlagunta M; Heena SK; Mutyala VVVP; Pawar SC
Med Oncol; 2022 Sep; 39(11):179. PubMed ID: 36048256
[TBL] [Abstract][Full Text] [Related]
5. DEAD-box RNA Helicase DDX3: Functional Properties and Development of DDX3 Inhibitors as Antiviral and Anticancer Drugs.
Kukhanova MK; Karpenko IL; Ivanov AV
Molecules; 2020 Feb; 25(4):. PubMed ID: 32102413
[TBL] [Abstract][Full Text] [Related]
6. In-Vitro and in-Silico characterization of Sophora interrupta plant extract as an anticancer activity.
Mathi P; Nikhil K; Ambatipudi N; Roy P; Bokka VR; Botlagunta M
Bioinformation; 2014; 10(3):144-51. PubMed ID: 24748754
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological inhibition of DEAD-Box RNA Helicase 3 attenuates stress granule assembly.
Cui BC; Sikirzhytski V; Aksenova M; Lucius MD; Levon GH; Mack ZT; Pollack C; Odhiambo D; Broude E; Lizarraga SB; Wyatt MD; Shtutman M
Biochem Pharmacol; 2020 Dec; 182():114280. PubMed ID: 33049245
[TBL] [Abstract][Full Text] [Related]
8. Identification of the DEAD box RNA helicase DDX3 as a therapeutic target in colorectal cancer.
Heerma van Voss MR; Vesuna F; Trumpi K; Brilliant J; Berlinicke C; de Leng W; Kranenburg O; Offerhaus GJ; Bürger H; van der Wall E; van Diest PJ; Raman V
Oncotarget; 2015 Sep; 6(29):28312-26. PubMed ID: 26311743
[TBL] [Abstract][Full Text] [Related]
9. A Computational Approach with Biological Evaluation: Combinatorial Treatment of Curcumin and Exemestane Synergistically Regulates DDX3 Expression in Cancer Cell Lines.
Rampogu S; Kim SM; Son M; Baek A; Park C; Lee G; Kim Y; Kim GS; Kim JH; Lee KW
Biomolecules; 2020 Jun; 10(6):. PubMed ID: 32512851
[TBL] [Abstract][Full Text] [Related]
10. DDX3, a DEAD box RNA helicase with tumor growth-suppressive property and transcriptional regulation activity of the p21waf1/cip1 promoter, is a candidate tumor suppressor.
Chao CH; Chen CM; Cheng PL; Shih JW; Tsou AP; Lee YH
Cancer Res; 2006 Jul; 66(13):6579-88. PubMed ID: 16818630
[TBL] [Abstract][Full Text] [Related]
11. DDX3 DEAD-Box RNA helicase inhibits hepatitis B virus reverse transcription by incorporation into nucleocapsids.
Wang H; Kim S; Ryu WS
J Virol; 2009 Jun; 83(11):5815-24. PubMed ID: 19297497
[TBL] [Abstract][Full Text] [Related]
12. A motif unique to the human DEAD-box protein DDX3 is important for nucleic acid binding, ATP hydrolysis, RNA/DNA unwinding and HIV-1 replication.
Garbelli A; Beermann S; Di Cicco G; Dietrich U; Maga G
PLoS One; 2011 May; 6(5):e19810. PubMed ID: 21589879
[TBL] [Abstract][Full Text] [Related]
13. (DEAD)-box RNA helicase 3 modulates NF-κB signal pathway by controlling the phosphorylation of PP2A-C subunit.
Wang X; Wang R; Luo M; Li C; Wang HX; Huan CC; Qu YR; Liao Y; Mao X
Oncotarget; 2017 May; 8(20):33197-33213. PubMed ID: 28402257
[TBL] [Abstract][Full Text] [Related]
14. Level of Murine DDX3 RNA Helicase Determines Phenotype Changes of Hepatocytes In Vitro and In Vivo.
Sergeeva O; Abakumova T; Kurochkin I; Ialchina R; Kosyreva A; Prikazchikova T; Varlamova V; Shcherbinina E; Zatsepin T
Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34203429
[TBL] [Abstract][Full Text] [Related]
15. DDX3 RNA helicase is required for HIV-1 Tat function.
Yasuda-Inoue M; Kuroki M; Ariumi Y
Biochem Biophys Res Commun; 2013 Nov; 441(3):607-11. PubMed ID: 24183723
[TBL] [Abstract][Full Text] [Related]
16. RNA helicase DDX3: a novel therapeutic target in Ewing sarcoma.
Wilky BA; Kim C; McCarty G; Montgomery EA; Kammers K; DeVine LR; Cole RN; Raman V; Loeb DM
Oncogene; 2016 May; 35(20):2574-83. PubMed ID: 26364611
[TBL] [Abstract][Full Text] [Related]
17. Combination treatment using DDX3 and PARP inhibitors induces synthetic lethality in BRCA1-proficient breast cancer.
Heerma van Voss MR; Brilliant JD; Vesuna F; Bol GM; van der Wall E; van Diest PJ; Raman V
Med Oncol; 2017 Mar; 34(3):33. PubMed ID: 28138868
[TBL] [Abstract][Full Text] [Related]
18. Toward the discovery of novel anti-HIV drugs. Second-generation inhibitors of the cellular ATPase DDX3 with improved anti-HIV activity: synthesis, structure-activity relationship analysis, cytotoxicity studies, and target validation.
Maga G; Falchi F; Radi M; Botta L; Casaluce G; Bernardini M; Irannejad H; Manetti F; Garbelli A; Samuele A; Zanoli S; Esté JA; Gonzalez E; Zucca E; Paolucci S; Baldanti F; De Rijck J; Debyser Z; Botta M
ChemMedChem; 2011 Aug; 6(8):1371-89. PubMed ID: 21698775
[TBL] [Abstract][Full Text] [Related]
19. Homology Model-Based Virtual Screening for the Identification of Human Helicase DDX3 Inhibitors.
Fazi R; Tintori C; Brai A; Botta L; Selvaraj M; Garbelli A; Maga G; Botta M
J Chem Inf Model; 2015 Nov; 55(11):2443-54. PubMed ID: 26544088
[TBL] [Abstract][Full Text] [Related]
20. RK-33 Radiosensitizes Prostate Cancer Cells by Blocking the RNA Helicase DDX3.
Xie M; Vesuna F; Tantravedi S; Bol GM; Heerma van Voss MR; Nugent K; Malek R; Gabrielson K; van Diest PJ; Tran PT; Raman V
Cancer Res; 2016 Nov; 76(21):6340-6350. PubMed ID: 27634756
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
